2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.119 (Poster) Real-World Use of Lurbinectedin in Patients With Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis

PP01.119 (Poster) Real-World Use of Lurbinectedin in Patients With Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis

Back to course

Pdf Summary

The study evaluated the real-world use of lurbinectedin in patients with small cell lung cancer (SCLC) who had previously received treatment. Lurbinectedin is a selective inhibitor of oncogenic transcription that was approved by the US Food and Drug Administration in 2020 for the treatment of metastatic SCLC.<br /><br />The study included 105 patients with a median age of 67 years. Most patients were over 65 years old. Approximately one-fifth of patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of greater than 2, and almost one-quarter had central nervous system involvement. More than two-thirds of patients had prior immunotherapy.<br /><br />The main findings of the study were that lurbinectedin was generally well-tolerated, with no new safety signals identified. The most common treatment-related adverse events were fatigue, febrile neutropenia, pneumonia, diarrhea, and skin ulcer. The most common laboratory abnormality was increased blood creatinine. Dose reductions and delays occurred in approximately one-quarter of patients, and 12% of patients discontinued treatment due to adverse events.<br /><br />The study also reported on the line of therapy in which lurbinectedin was administered. Approximately half of the patients received lurbinectedin as second-line therapy. The median number of treatment cycles administered was four, with a median duration of treatment exposure of 97.0 days.<br /><br />In conclusion, the interim analysis of this real-world study showed that lurbinectedin was well-tolerated and had a safety profile consistent with previous studies. The findings support the use of lurbinectedin as a treatment option for patients with relapsed small cell lung cancer.

Asset Subtitle

Firas Badin

Keywords

lurbinectedin

small cell lung cancer

SCLC

oncogenic transcription

metastatic SCLC

treatment

immunotherapy

adverse events

line of therapy

real-world study